Celldex Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anthony S. Marucci
- Full Time Employees
- 198
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Perryville III Building Hampton NJ United States of America 08827
- IPO Date
- May 15, 1986
- CIK
- 0000744218
- Website
- celldex.com
- Similar Companies
- Business
- Celldex Therapeutics, Inc. (CLDX) develops novel antibody-based immunotherapies targeting mast cell-mediated inflammatory, allergic, and autoimmune diseases. The company's lead product candidate, barzolvolimab (CDX-0159), a humanized monoclonal antibody KIT antagonist, advances in Phase 3 trials for chronic spontaneous urticaria and Phase 2 trials for cold urticaria, symptomatic dermographism, prurigo nodularis, and atopic dermatitis; CDX-622, a TSLP/SCF bispecific antibody, progresses in Phase 1 healthy volunteer studies to deplete mast cells and inhibit Type 2 inflammation in broader inflammatory and fibrotic disorders. Founded in 1983 and headquartered in Hampton, New Jersey, Celldex operates primarily in the United States with a focus on clinical-stage biopharmaceutical development for immunology indications and targets patients with severe mast cell-driven conditions. Recent developments include positive Phase 3 data for barzolvolimab reinforcing its pipeline-in-a-product potential, a proposed public offering of common stock to fund ongoing trials, and third quarter 2025 financial results highlighting pipeline advancement amid strategic collaborations for commercialization support.
Celldex Announces Planned Transition of Chief Financial Officer
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex Reports First Quarter Financial Results and Provides Corporate Update
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment
Celldex to Present at Upcoming Investor Conference
SG Americas Securities LLC Has $1.29 Million Holdings in Celldex Therapeutics, Inc. $CLDX
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
Celldex Announces Proposed Public Offering of Common Stock
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update